Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.45 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276453 | 0.82 | ABCC1 (0.53) | RXRARXRBRXRGMEN1KMT2A | |
| Formic Acid SCHEMBL6820433 | 0.79 | ACHE (0.47) | RXRARXRBRXRGKDM4EACHE | |
| SCHEMBL7392586 | 0.78 | MEN1 (0.52) | RXRARXRBRXRGACHETAS2R14 | |
| SCHEMBL15840792 | 0.77 | HCAR3 (0.45) | KDM4EALDH1A1LMNA | |
| SCHEMBL642243 | 0.77 | HCAR3 (0.53) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL11344382 | 0.76 | KDM4C (0.51) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL15840793 | 0.76 | HCAR3 (0.50) | KDM4EALDH1A1 | |
| SCHEMBL26023444 | 0.76 | RXRA (0.58) | RXRARXRBRXRGTAS2R14MEN1 | |
| SCHEMBL28325048 | 0.75 | MAPT (0.49) | RXRARXRBRXRGACHEMEN1 | |
| SCHEMBL11108577 | 0.75 | ACHE (0.49) | RXRARXRBRXRGKDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100004207-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH INC. | 2010-01-07 | — | — | US | disclosed |
| US-7605175-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH AG (DE) | 2009-10-20 | — | — | US | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-7135550-B2 | Compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds | GPC BIOTECH INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1364212-A4 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2005-05-04 | — | — | EP | disclosed |
| US-20040266854-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH, INC. (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040266853-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH, INC. (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040043388-A1 | Three hybrid assay system | GPC BIOTECH AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1364212-A2 | THREE HYBRID ASSAY SYSTEM | GPC Biotech AG (DE) | 2003-11-26 | — | — | EP | disclosed |
| US-20030165873-A1 | For isolating ligand binding polypeptides; fusion proteins; drug screening; kits; surface plasmon resonance | GPC BIOTECH AG (DE) | 2003-09-04 | — | — | US | disclosed |
| WO-2002070662-A2 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266853-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | RXRA 3552/4885RXRB 3415/4885RXRG 3150/4885 |
| US-20030165873-A1 | For isolating ligand binding polypeptides; fusion proteins; drug screening; kits; surface plasmon resonance | MST1R, PLAUR, SPR | RXRA 1905/4885RXRB 1519/4885RXRG 1163/4885 |
| US-20100004207-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | RXRA 3552/4885RXRB 3415/4885RXRG 3150/4885 |
| US-20040043388-A1 | Three hybrid assay system | ACKR3, KLK3, TIMCC | RXRA 2782/4885RXRB 2398/4885RXRG 2275/4885 |
| US-20040266854-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | RXRA 3552/4885RXRB 3415/4885RXRG 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.